公司资料
Ensysce Biosciences 股价、新闻与催化剂
- 股票代码:
- ENSC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.38 USD (-5.83%)
收盘价
最后更新: 2026年8月17日
3.84M USD
市值
股价为何变动
As of Aug 17, 2026, ENSC closed down 5.83% at $0.3766. No new same-company headline was identified in the current news window.
公司概览
Complex-Pain Therapeutics
Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain. The company expanded its strategy through the acquisition of Cy Biopharma.
CY200
CY200 is an orphan-designated neuroplastogenic candidate for complex regional pain syndrome type 1. It is designed to address the underlying neurobiology of the disorder rather than only managing symptoms.
Protected Opioid Platform
Ensysce's Trypsin-Activated Abuse Protection technology keeps opioid prodrugs inactive until they reach the small intestine. PF614 applies this approach to an extended-release oxycodone product.
Overdose-Protection Program
PF614-MPAR combines abuse protection with Multi-Pill Abuse Resistance technology intended to limit oral overdose. The program has received FDA Breakthrough Therapy designation.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。